Alzheimer’s disease is a progressive brain disorder that slowly erodes memory, thinking, and daily functioning. While current medications can ease symptoms, they do not stop the disease from advancing. Researchers are now exploring noninvasive brain-based therapies that may directly influence the biological processes behind Alzheimer’s. One approach gaining attention is 40Hz light and sound therapy for Alzheimer’s disease, also known as gamma entrainment using sensory stimuli or GENUS.
What Is 40Hz Light and Sound Therapy
40Hz light and sound therapy uses rhythmic visual and auditory stimulation to gently guide the brain into a specific pattern of activity called gamma waves. Gamma waves at 40Hz are linked to attention, memory, and healthy communication between brain cells.
In this therapy, participants are exposed to flickering light and pulsing sound for about one hour per day, often using simple devices at home. The goal is to synchronize brain activity without surgery, medications, or electrical stimulation.
Why Gamma Waves Matter in Alzheimer’s Disease
In Alzheimer’s disease, normal gamma wave activity is often disrupted. Earlier laboratory studies showed that restoring 40Hz gamma rhythms in animals reduced amyloid and tau proteins, preserved neurons, and improved memory.
These findings led scientists to ask whether the same mechanism could help people with Alzheimer’s disease, especially in its early stages.
New Long-Term Human Findings From MIT Researchers
A recent long-term follow-up study from researchers at MIT examined five volunteers with mild Alzheimer’s disease who used daily 40Hz light and sound therapy for nearly two years. Three participants had late-onset Alzheimer’s disease, while two had early-onset forms.
The results were most notable for the late-onset group. These participants maintained stronger cognitive performance compared to similar patients in national Alzheimer’s databases. They also showed better sleep patterns and more stable circadian rhythms over time.
Biomarker Changes Suggest Biological Impact
Beyond cognitive testing, the study also measured biological markers of Alzheimer’s disease. Two late-onset participants provided blood samples, and both showed significant reductions in plasma tau levels.
Tau is a key protein involved in Alzheimer’s pathology and is closely linked to disease progression. Reductions in tau suggest that 40Hz light and sound therapy for Alzheimer’s disease may do more than support symptoms. It may influence the underlying disease process itself.
Why Early-Onset Patients Responded Differently
The two participants with early-onset Alzheimer’s disease did not experience the same benefits. Researchers observed reduced brain-wave responsiveness to the stimulation in these individuals.
This difference may reflect distinct biological pathways between early-onset and late-onset Alzheimer’s disease rather than gender differences. These findings highlight the importance of identifying which patients are most likely to benefit from gamma-based therapies.
Safety and At-Home Feasibility
One of the most encouraging aspects of 40Hz light and sound therapy is its safety profile. Participants tolerated daily use well, with no serious adverse effects reported.
Because the therapy is noninvasive and designed for home use, it could become a scalable option for long-term brain health support if larger clinical trials confirm its effectiveness.
What Comes Next for Gamma Entrainment Research
Larger randomized clinical trials are now underway, including studies focused on prevention in adults with higher genetic risk for Alzheimer’s disease.
Future research will explore who responds best, how long benefits last, and whether combining gamma stimulation with other treatments enhances outcomes. While still experimental, 40Hz light and sound therapy for Alzheimer’s disease represents a promising shift toward accessible, brain-based interventions that target disease biology rather than symptoms alone.
disease biology rather than symptoms alone.
Citations
Chan D, et al. Gamma sensory stimulation in mild Alzheimer’s dementia: An open-label extension study. Alzheimer’s & Dementia. 2025. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70792
Study suggests 40Hz sensory stimulation may benefit some Alzheimer’s patients for years. MIT News. Nov 14, 2025. https://news.mit.edu/2025/study-suggests-40hz-sensory-stimulation-may-benefit-some-alzheimers-patients-1114